Skip to main content

Main menu

  • Home
  • Content
    • Current Issue
    • Ahead of Print
    • Past Issues
    • Supplements
    • Article Type
  • Specialty
    • Articles by Specialty
  • CME/MOC
    • Articles
    • Calendar
  • Info For
    • Manuscript Submission
    • Authors & Reviewers
    • Subscriptions
    • About CCJM
    • Contact Us
    • Media Kit
  • Conversations with Leaders
  • Conference Coverage
    • Kidney Week 2024
    • CHEST 2024
    • ACR Convergence 2023
    • Kidney Week 2023
    • ObesityWeek 2023
    • IDWeek 2023
    • CHEST 2023
    • MDS 2023
    • IAS 2023
    • ACP 2023
    • AAN 2023
    • ACC / WCC 2023
    • AAAAI Meeting 2023
    • ACR Convergence 2022
    • Kidney Week 2022
    • AIDS 2022
  • Other Publications
    • www.clevelandclinic.org

User menu

  • Register
  • Log in

Search

  • Advanced search
Cleveland Clinic Journal of Medicine
  • Other Publications
    • www.clevelandclinic.org
  • Register
  • Log in
Cleveland Clinic Journal of Medicine

Advanced Search

  • Home
  • Content
    • Current Issue
    • Ahead of Print
    • Past Issues
    • Supplements
    • Article Type
  • Specialty
    • Articles by Specialty
  • CME/MOC
    • Articles
    • Calendar
  • Info For
    • Manuscript Submission
    • Authors & Reviewers
    • Subscriptions
    • About CCJM
    • Contact Us
    • Media Kit
  • Conversations with Leaders
  • Conference Coverage
    • Kidney Week 2024
    • CHEST 2024
    • ACR Convergence 2023
    • Kidney Week 2023
    • ObesityWeek 2023
    • IDWeek 2023
    • CHEST 2023
    • MDS 2023
    • IAS 2023
    • ACP 2023
    • AAN 2023
    • ACC / WCC 2023
    • AAAAI Meeting 2023
    • ACR Convergence 2022
    • Kidney Week 2022
    • AIDS 2022
Review

Thoracic aortic aneurysm: Optimal surveillance and treatment

Tom Kai Ming Wang, MBCHB, MD(res), FRACP and Milind Y. Desai, MD
Cleveland Clinic Journal of Medicine September 2020, 87 (9) 557-568; DOI: https://doi.org/10.3949/ccjm.87a.19140-1
Tom Kai Ming Wang
Advanced Cardiac Imaging Fellow, Section of Cardiovascular Imaging, Heart, Vascular, and Thoracic Institute, Cleveland Clinic
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: [email protected]
Milind Y. Desai
Staff Cardiologist, Section of Cardiovascular Imaging and Medical Director, Aorta Center, Heart, Vascular, and Thoracic Institute, Cleveland Clinic; Professor, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Figures & Data

Figures

  • Tables
  • Figure 1
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 1

    Computed tomography angiography aortic root measurements on (A) axial source image and (B–D) 3-dimensional multiplanar reconstruction (3-D-MPR) double-oblique planes. Note that without 3-D-MPR, the aortic root size is underestimated (A). Also note that sinus-commissure measurements are often slightly less than sinus-sinus measurements in (B).

  • Figure 2
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 2

    Computed tomography of thoracic aortic aneurysm without (A) and with (B) electrocardiographic gating. Note that the motion artifact indicated by the white arrow in (A) is not seen in (B).

  • Figure 3
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 3

    Range of thoracic aortic aneurysm (TAA) pathologies: (A) bicuspid aortic valve aortopathy on computed tomography (CT), (B) Marfan syndrome with pectus excavatum on magnetic resonance imaging, (C) mycotic aortic arch aneurysm on CT, (D) Takayasu arteritis on CT, with thickened, inflamed aortic wall.

  • Figure 4
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 4

    Cross-sectional area-to-height ratio and management-stratification Kaplan-Meier survival curves for (A) aortic root and (B) ascending aorta in 969 consecutive patients with bicuspid aortic valve with proximal aorta diameter ≥ 4 cm, who underwent gated contrast-enhanced thoracic computed tomography or magnetic resonance angiography. Note the worse outcomes for those with aortic root area-to-height ratio > 10 cm2/m, in whom surgery makes a big difference in survival.

    Reprinted from Masri A, Kalahasti V, Svensson LG, et al. Aortic cross-sectional area/height ratio and outcomes in patients with bicuspid aortic valve and a dilated ascending aorta. Circ Cardiovasc Imaging 2017; 10(6):e006249. doi:10.1161/CIRCIMAGING.116.00624

Tables

  • Figures
    • View popup
    TABLE 1

    Thoracic aortic aneurysm: Risk factors, associations, and causes

    Risk factors
    Older age
    Male sex
    Hypertension
    Smoking
    Hypercholesterolemia
    Weight-lifting
    Cocaine use
    Trauma
    Cardiovascular associations
    Atherosclerosis
    Bicuspid aortic valve
    Other aneurysm
    Prior aortic dissection
    Aortic coarctation
    Genetic causes
    Familial thoracic aortic aneurysm
    Marfan syndrome
    Loeys-Dietz syndrome
    Ehlers-Danlos syndrome
    Turner syndrome
    Autosomal-dominant polycystic kidney disease
    Shprintzen-Goldberg (craniosynostosis) syndrome
    Inflammatory causes
    Takayasu arteritis
    Giant-cell arteritis
    Behçet arteritis
    Ankylosing spondylitis
    Infective causes
    Mycotic aortitis
    Syphilis
    Idiopathic
    • View popup
    TABLE 2

    Imaging options for assessing thoracic aortic aneurysm

    ConsiderationsTTETEECTAMRAAortography
    Accuracy of measurementMediumMediumHighHighLow
    Extent of aortic assessmentLimitedMediumEntireEntireLimited
    Detecting acute aortic syndromesPoorMediumHighHighPoor
    Aortic regurgitation and gradingYesYesNoYesLimited
    PortableYesYesNoNoNo
    ContrastNoNoYesYesYes
    RadiationNoNoYesNoYes
    CostLowMediumMediumHighHigh
    Invasive procedureNoYesNoNoYes
    Recommended line of investigationSecondThirdFirstSecondThird
    • CTA = computed tomography angiography; MRA = magnetic resonance angiography; TEE = transesophageal echocardiography; TTE = transthoracic echocardiography

    • Based on information in reference 9.

    • View popup
    TABLE 3

    Indications for prophylactic intervention for thoracic aortic aneurysm

    Aneurysm location and associated conditionsACC/AHA 20102ESC 20141Our recommendation
    Ascending aorta
    No associated conditions
     
    ≥ 5.5 cm (I-C)a
    ≥ 0.5 cm/year growth (I-C)
     
    ≥ 5.5 cm (I-C), lower if small stature, rapid progression, aortic regurgitation (AR), pregnancy, patient preference (IIa-C)
     
    ≥ 5.5 cm
    π r2/H > 10
    Aortic valve surgery planned> 4.5 cm (I-C)> 4.5 cm> 4.5 cm
    Marfan syndrome4.0–5.0 cm (I-C)
    π r2/H > 10 (IIa-C)
    ≥ 5.0 cm (I-C)
    > 4.5 cm with risk factors or family history (IIa-C)
    ≥ 0.3 cm/year growth, severe AR, pregnancy desired (IIa-C)
    > 4.5 cm
    π r2/H > 10
    Bicuspid aortic valve≥ 4.0–5.0 cm (I-C)
    π r2/H > 10 (IIa-C)
    ≥ 5.5 cm without risk factors (I-C)
    ≥ 5.0 cm with risk factors, family history, hypertension, aortic coarctation (I-C)
    ≥ 4.5 cm if AVR planned (I-C)
    ≥ 0.3 cm/year growth (IIa-C)
    ≥ 5.0 cm without risk factors
    ≥ 4.5 cm with risk factors
    π r2/H > 10
    Turner syndrome4.0–5.0 cm (I-C)
    π r2/H > 10 (IIa-C)
    Indexed aortic diameter ≥ 27.5 mm/m2≥ 27.5 mm/m2
    π r2/H > 10
    Loeys-Dietz syndrome (apply to TGFBR1 or TGFBR2 mutation)≥ 4.2 cm (TEE) (IIa-C)
    ≥ 4.4–4.6 cm (CTA/MRA)
    (IIa-C)
    ≥ 5.0 cm (I-C)
    ≥ 4.5 cm with risk factors (IIa-C)
    ≥ 4.5 cm
    π r2/H > 10
    Ehlers-Danlos syndrome4.0–5.0 cm (I-C)
    π r2/H > 10 (IIa-C)
    No specific threshold recommended≥ 4.5 cm
    π r2/H > 10
    Familial TAA4.0–5.0 cm (I-C)
    π r2/H > 10 (IIa-C)
    No specific threshold recommended≥ 4.5 cm
    π r2/H > 10
    Aortic arch
    None
     
    ≥ 5.5 cm (IIa-B)
     
    ≥ 5.5 cm (IIa-C)
    Consider if having ascending or descending TAA surgery (IIa-C)
     
    ≥ 5.5 cm
    Descending aorta
    Stent graft
     
    ≥ 5.5 cm (I-B)
     
    ≥ 5.5 cm (IIa-C)
     
    ≥ 5.5 cm
    Surgery≥ 6.0 cm (I-C) (include high risk, thoracoabdominal)≥ 6.0 cm (IIa-C)≥ 6.0 cm
    Surgery with degenerative, traumatic or saccular TAA, or postoperative pseudo-aneurysm≥ 5.5 cm (I-B)No specific threshold recommended≥ 5.5 cm
    Surgery with connective tissue disorder like Marfan or Loeys-Dietz syndromeLower threshold than > 6 cm (I-C)Lower threshold than > 6 cm≥ 5.5 cm
    • ↵a Class of recommendation (scale of I to III) and level of evidence (scale of A to C).

    • ACC = American College of Cardiology; AHA = American Heart Association; AVR = aortic valve surgery; CTA = computed tomographic angiography; ESC = European Society of Cardiology; MRA = magnetic resonance angiography π r2/H = maximal cross-sectional area of TAA divided by height; TAA = thoracic aortic aneurysm

    • View popup
    TABLE 4

    Recommendations for measurement and surveillance of thoracic aortic aneurysms

    Associated conditionsACC/AHA 20102ESC 20141ASE/EACVI 20153Our recommendations
    NoneNo specific recommendations except needing surveillanceNo specific recommendations except needing surveillanceEvery 1–3 years based on risk after diagnosisTTE and CTA or MRA at baseline and 6 months; If TAA < 5.0 cm and stable, then yearly
    If TAA ≥ 5.0 cm or growing > 0.5 cm/year, then every 6 months and refer to surgeon
    Marfan syndromeMeasure dimensions and maximum cross-sectional area divided by height
    TTE at baseline and 6 months, CTA or MRA at baseline to check TTE
    If stable and < 4.5 cm, then yearly after, if not then more frequently
    TTE and MRA or CTA
    If no TAA at baseline, TTE yearly, MRA or CTA every 5 years
    If any aneurysm is above root, MRA or CTA yearly
    Refer to 2010 ESC adult congenital disease guidelines35
    Dimensions with normative values based on age, body surface area, and Z scores
    TTE and CTA or MRA
    If no TAA at baseline, then every 2–3 years
    First TAA diagnosis: 6 months then yearly if stable, < 4.5 cm and no dissection history; otherwise every 6 months
    Postoperatively: 6 months, then yearly if stable CTA or MRA at least every 3 years if using TTE
    TTE and CTA or MRA at baseline
    and 6 months
    If no TAA, then TTE yearly and CTA or MRA every 2 years
    First TAA diagnosis: TTE and CTA or MRA yearly if stable (< 0.3 cm/year) and < 4.5 cm, other-wise every 6 months and refer to surgeon
    Bicuspid aortic valveNo specific recommendations after initial imaging TTE and CTA or MRATTE and CTA or MRA
    If no TAA at baseline, repeat TTE yearly
    If TAA > 4.5 cm or growing at > 3 mm/year, then do CTA or MRA to confirm at same time, then yearly
    TTE and CTA or MRA
    If no at baseline, repeat every 3–5 years
    First TAA diagnosis: 6 months then yearly if stable, < 4.5 cm and no dissection history; otherwise every 6 months
    Postoperatively: yearly but individualize
    TTE + CTA or MRA at baseline and 6 months
    No TAA: TTE yearly and CTA or MRA every 2 years
    First TAA diagnosis: TTE and CTA or MRA yearly if stable (< 0.3 cm/year) and < 4.5 cm, other-wise every 6 months and refer to surgeon
    Turner syndromeBaseline TTE and CTA or MRA
    If no TAA or dissection risk factors, repeat every 5–10 years
    If no TAA: TTE every 3–5 years for low risk, MRA every 3–5 years for moderate risk, and MRI every 1–2 years for high riskIndex dimensions by body surface area; if indexed diameter > 2 cm/m2, repeat yearlyTTE + CTA or MRA at baseline and 6 months
    Index dimensions by body surface area
    No TAA: TTE yearly and CTA or MRA every 2 years
    Indexed diameter > 2 cm/m2: yearly MRA or CTA and refer to surgeon
    Familial TAANo specific recommendations after initial imaging TTE and CTA or MRANo specific recommendations after initial imaging TTE and CTA or MRAFollow plan for Marfan syndrome, but individualizeTTE + CTA or MRA at baseline and 6 months
    Follow plan for Marfan syndrome but individualize risk
    Loeys-Dietz syndromeBaseline and 6 months TTE and CTA or MRA, then yearly if stable
    Whole-body MRA
    No specific recommendations after initial imaging TTE and CTA or MRAEvery 1–3 years depending on risk, every 6 months if progressionTTE + CTA or MRA at baseline and 6 months
    Yearly if low risk, < 4.0 cm and stable (< 0.3 cm/year), otherwise every 6 months and refer to surgeon
    Ehlers-Danlos syndromeNo specific recommendationsNo specific recommendations, individualizeNo specific recommendationsTTE + CTA or MRA at baseline and 6 months
    No specific recommendation for surveillance
    • ACC = American College of Cardiology; AHA = American Heart Association; ASE = American Society of Echocardiography;

    • CTA = computed tomography angiography; EACVI = European Association of Cardiovascular Imaging; ESC = European Society of Cardiology;

    • MRA = magnetic resonance angiography; MRI = magnetic resonance imaging; TAA = thoracic aortic aneurysm; TTE = transthoracic echocardiography

PreviousNext
Back to top

In this issue

Cleveland Clinic Journal of Medicine: 87 (9)
Cleveland Clinic Journal of Medicine
Vol. 87, Issue 9
1 Sep 2020
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Complete Issue (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Cleveland Clinic Journal of Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Thoracic aortic aneurysm: Optimal surveillance and treatment
(Your Name) has sent you a message from Cleveland Clinic Journal of Medicine
(Your Name) thought you would like to see the Cleveland Clinic Journal of Medicine web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Thoracic aortic aneurysm: Optimal surveillance and treatment
Tom Kai Ming Wang, Milind Y. Desai
Cleveland Clinic Journal of Medicine Sep 2020, 87 (9) 557-568; DOI: 10.3949/ccjm.87a.19140-1

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Thoracic aortic aneurysm: Optimal surveillance and treatment
Tom Kai Ming Wang, Milind Y. Desai
Cleveland Clinic Journal of Medicine Sep 2020, 87 (9) 557-568; DOI: 10.3949/ccjm.87a.19140-1
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Linkedin Share Button

Jump to section

  • Article
    • ABSTRACT
    • WHAT IS THE CLINICAL IMPORTANCE OF TAA?
    • WHO IS AT RISK?
    • HOW IS TAA DISCOVERED?
    • WHAT IS A NORMAL-SIZE AORTA?
    • WHAT IMAGING MODALITIES ARE USED?
    • WHEN SHOULD TAA BE FIXED?
    • HOW SHOULD TAA BE MONITORED?
    • DO DRUGS SLOW THE RATE OF TAA EXPANSION?
    • HOW SHOULD TAA BE FIXED?
    • WHAT ELSE SHOULD BE MANAGED?
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

  • PubMed
  • Google Scholar

Cited By...

  • Optimal surveillance and treatment of renal and splenic artery aneurysms
  • Google Scholar

More in this TOC Section

  • Alpha-gal syndrome: Recognizing and managing a tick-bite–related meat allergy
  • Managing right ventricular failure in the setting of pulmonary embolism
  • Psychedelics, spirituality, and existential distress in patients at the end of life
Show more Review

Similar Articles

Subjects

  • Cardiology
  • Genetics
  • Imaging
  • Preventive Care
  • Vascular Medicine

Navigate

  • Current Issue
  • Past Issues
  • Supplements
  • Article Type
  • Specialty
  • CME/MOC Articles
  • CME/MOC Calendar
  • Media Kit

Authors & Reviewers

  • Manuscript Submission
  • Authors & Reviewers
  • Subscriptions
  • About CCJM
  • Contact Us
  • Cleveland Clinic Center for Continuing Education
  • Consult QD

Share your suggestions!

Copyright © 2025 The Cleveland Clinic Foundation. All rights reserved. The information provided is for educational purposes only. Use of this website is subject to the website terms of use and privacy policy. 

Powered by HighWire